These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25409918)

  • 1. Simulation of in vitro dissolution behavior using DDDPlus™.
    Almukainzi M; Okumu A; Wei H; Löbenberg R
    AAPS PharmSciTech; 2015 Feb; 16(1):217-21. PubMed ID: 25409918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
    Wei H; Löbenberg R
    Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug.
    Okumu A; DiMaso M; Löbenberg R
    Pharm Res; 2008 Dec; 25(12):2778-85. PubMed ID: 18560996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.
    Guimarães M; Somville P; Vertzoni M; Fotaki N
    AAPS J; 2022 Jan; 24(1):26. PubMed ID: 35013835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Predictive Dissolution Testing of Montelukast Sodium Formulations Administered with Drinks and Soft Foods to Infants.
    Martir J; Flanagan T; Mann J; Fotaki N
    AAPS PharmSciTech; 2020 Oct; 21(7):282. PubMed ID: 33051713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of in vivo drug performance using in vitro dissolution coupled with STELLA: a study with selected drug products.
    Chakraborty S; Yadav L; Aggarwal D
    Drug Dev Ind Pharm; 2015; 41(10):1667-73. PubMed ID: 25494535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation and evaluation of a montelukast sodium orally disintegrating tablet with a similar dissolution profile as the marketed product.
    Chen Y; Feng T; Li Y; Du B; Weng W
    Pharm Dev Technol; 2017 Mar; 22(2):168-172. PubMed ID: 26654222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products.
    Okumu A; DiMaso M; Löbenberg R
    Eur J Pharm Biopharm; 2009 May; 72(1):91-8. PubMed ID: 19056493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach.
    Guimarães M; Vertzoni M; Fotaki N
    AAPS J; 2022 Jan; 24(1):27. PubMed ID: 35013803
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Silva TMD; Honorio TDS; Chaves MHDC; Duque MD; Cabral LM; Patricio BFC; Rocha HVA
    Drug Dev Ind Pharm; 2021 Aug; 47(8):1342-1352. PubMed ID: 34622730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations.
    Martir J; Flanagan T; Mann J; Fotaki N
    AAPS PharmSciTech; 2020 Oct; 21(7):287. PubMed ID: 33063245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in silico characterisation of Tacrolimus released under biorelevant conditions.
    Mercuri A; Wu S; Stranzinger S; Mohr S; Salar-Behzadi S; Bresciani M; Fröhlich E
    Int J Pharm; 2016 Dec; 515(1-2):271-280. PubMed ID: 27737809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico Tools at Early Stage of Pharmaceutical Development: Data Needs and Software Capabilities.
    Njoku JO; Amaral Silva D; Mukherjee D; Webster GK; Löbenberg R
    AAPS PharmSciTech; 2019 Jul; 20(6):243. PubMed ID: 31264126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form.
    Jantratid E; De Maio V; Ronda E; Mattavelli V; Vertzoni M; Dressman JB
    Eur J Pharm Sci; 2009 Jun; 37(3-4):434-41. PubMed ID: 19491035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in vitro--in silico--in vivo approach in biopharmaceutical drug characterization: metformin hydrochloride IR tablets.
    Beloica S; Cvijić S; Homšek I; Bogataj M; Parojčić J
    Pharmazie; 2015 Jul; 70(7):458-65. PubMed ID: 26373206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Justification of disintegration testing beyond current FDA criteria using in vitro and in silico models.
    Uebbing L; Klumpp L; Webster GK; Löbenberg R
    Drug Des Devel Ther; 2017; 11():1163-1174. PubMed ID: 28442890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the oral pharmacokinetic profiles of multiple-unit (pellet) dosage forms using a modeling and simulation approach coupled with biorelevant dissolution testing: case example diclofenac sodium.
    Kambayashi A; Blume H; Dressman JB
    Eur J Pharm Biopharm; 2014 Jul; 87(2):236-43. PubMed ID: 24462791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation of ternary complexes of glyburide with hydroxypropyl-β-cyclodextrin and other solubilizing agents and their effect on release behavior of glyburide in aqueous and buffered media at different agitation speeds.
    Singh SK; Srinivasan KK; Singare DS; Gowthamarajan K; Prakash D
    Drug Dev Ind Pharm; 2012 Nov; 38(11):1328-36. PubMed ID: 22283512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of a ternary HP-β-CD-complex approach to improve the dissolution performance of a poorly soluble weak acid under biorelevant conditions.
    Zoeller T; Dressman JB; Klein S
    Int J Pharm; 2012 Jul; 430(1-2):176-83. PubMed ID: 22531855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based pharmacokinetic model outputs depend on dissolution data and their input: Case examples glibenclamide and dipyridamole.
    Klumpp L; Dressman J
    Eur J Pharm Sci; 2020 Aug; 151():105380. PubMed ID: 32442630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.